Key facts
- LinusBio’s last known valuation is $171.2M (Jul 2024).
- It has raised $34.6M; the latest was Later Stage VC ($3.0M) in Jun 2025.
- Notable investors include GreatPoint Ventures, Bow Capital, Crom Capital Management, David Bellet Family Office, Divergent Investments — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for LinusBio
- ·The full record, as it builds
Funding rounds
No funding rounds for LinusBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LinusBio
Developer of a precision exposome medicine platform designed to analyze the molecular impact of environmental exposures on health. The company offers a temporal exposome sequencing technology, enabling healthcare providers to identify novel biomarkers and improve the diagnosis and treatment of complex conditions like CNS and GI disorders.
- Sector
- Healthcare
- HQ
- North Brunswick, NJ, United States
- Founded
- 2020
- Employees
- 39
- Website
- linusbio.com/
- Ownership
- Privately Held (backing)
LinusBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LinusBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LinusBio in its N-PORT filings yet. We sweep new filings monthly.